Aug 26, 2020 7:00 am EDT Cerecor Resumes Phase 1b Clinical Trial of CERC-002 for the Treatment of Severe Pediatric Onset Crohn’s Disease
Aug 13, 2020 7:00 am EDT Cerecor Announces Peer-Reviewed Publication Highlighting the Role of the Inflammatory Cytokine, LIGHT, in COVID-19 ARDS
Aug 4, 2020 7:00 am EDT Cerecor Receives Rare Pediatric Disease Designation for CERC-006 in Lymphatic Malformations
Aug 3, 2020 7:00 am EDT Cerecor Receives Orphan Drug Designation for CERC-006 in Lymphatic Malformations
Jul 21, 2020 7:00 am EDT Cerecor Announces First Patient Enrolled in Multicenter Proof-of-Concept Study Evaluating CERC-002 for COVID-19 ARDS
Jun 11, 2020 1:30 pm EDT Cerecor Inc. Announces Closing of $37.95 Million Public Offering and Full Exercise of Underwriter’s Option to Purchase Additional Shares
Jun 9, 2020 9:05 am EDT Cerecor Inc. Announces Pricing of $33,000,000 Public Offering of Common Stock
